Quoin Pharmaceuticals gains Orphan Drug Designation
- Orphan Drug Designation for QRX003 in Europe for Peeling Skin Syndrome
- 10 years of market exclusivity if approved in Europe
- First-ever clinical study for Peeling Skin Syndrome planned before year end